Abstract
La enfermedad de Parkinson es la segunda enfermedad degenerativa más común en el mundo después del Alzheimer. En Colombia hay una prevalencia estimada de 4,7 (IC95%: 2,2 a 8,9) por 1,000 habitantes y se detecta con mayor frecuencia en personas mayores de 60 años, lo que representa un alto costo para las familias y para el sistema de salud. Actualmente se utilizan para el diagnóstico los criterios del Banco de Cerebros del Reino Unido, sin embargo, hay otros criterios que pueden ser útiles para proyectos de investigación. Se ha demostrado que hay múltiples factores de riesgo y de progresión asociados con la enfermedad, y que deben tenerse en cuenta durante la evaluación clínica, la cual debería siempre realizarse en conjunto con las escalas de seguimiento.
References
WIRDEFELDT K, ADAMI H-O, COLE P, TRICHOPOULOS D, MANDEL J. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. European journal of epidemiology 2011;26:S1–58.
Gustavo Pradilla A., 1 Boris E. Vesga A., 2 3 FEL-S3 y grupo G. Estudio neuroepidemiológico nacional (EPINEURO)
colombiano. Pan Am J Public Health. 2003;14(2):104 - 110.
WOOTEN GF, CURRIE LJ, BOVBJERG VE, LEE JK PJ. Are men at greater risk for Parkinson’s disease than women? J Neurol Neurosurg Psychiatry. 2004;75:637-639.
TAYLOR KS, COOK JA CC. Heterogeneity in male to female risk for Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78:905 - 906.
HIRTZ D, THURMAN DJ, GWINN-HARDY K, MOHAMED M, CHAUDHURI A R, ZALUTSKY R. How common are the “common” neurologic disorders? Neurology. 2007, Jan, 30;68(5):326–327.
DORSEY ER, CONSTANTINESCU R, THOMPSON JP, BIGLAN KM, HOLLOWAY RG, KIEBURTZ K, ET AL. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384–386.
DANE (Departamento Administrativo Nacional de Estadística); Centro Andino de Altos Estudios CANDANE. Proyecciones nacionales y departamentales de población 2005 - 2020.
PMU iniciativa del I y del C. Monográfico sobre Colombia Indicadores básicos. Portal Mayores. 2011; http://www.imsersomayores.csic.es/internacional/iberoamerica/colombia/indicadores.html
REESE JP, DAMS J, WINTER Y, BALZER-GELDSETZERM, OERTEL WH, DODEL R. Pharmacoeconomic considerations of treating patients with advanced Parkinson’s disease. Expert Opin. Pharmacother. 2012;13(7):939–58.
DANIEL SE, KILFORD L, LEES AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological
study of 100 cases. Journal of Neurology, Neurosurgery, and Psychiatry. 1992;55:181–184.
GELB DJ, OLIVER E, GILMAN S. Diagnostic criteria for Parkinson disease. Archives of neurology. 1999, Jan;56(1):33–39.
BAUMANN CR. Epidemiology, diagnosis and differential diagnosis in Parkinson’s disease tremor. Parkinsonism & related disorders. 2012, Jan;18 Suppl 1:S90–92.
D.A. PINEDA A B, O. BURITICA A, C , J.L. SÁNCHEZ A, C, C.S. URIBE A, D AA. Síndromes parkinsonianos en Medellín (Colombia). Revista De Neurología. 2000;31(10):936–943.
POLYMEROPOULOS MH, LAVEDAN C, LEROY E, IDE SE, DEHEJIA A, DUTRA A ET AL. Mutation in the alphasynuclein gene identified in families with Parkinson’s disease. Science. 1997;276:2045 - 2047.
LILL CM, ROEHR JT, MCQUEEN MB, KAVVOURA FK, BAGADE S, SCHJEIDE B-MM, ET AL. Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson’s Disease Genetics: The PDGene Database. PLoS Genetics. 2012, Mar, 15;8(3):1–10.
MCCULLOCH CC, KAY DM, FACTOR SA, SAMII A, NUTT JG, HIGGINS DS ET AL. Exploring gene-environment interactions in Parkin- son’s disease. Hum Genet. 2008;123:257–65.
HUTTON M, LENDON CL, RIZZU P, BAKER M, FROELICH S, HOULDEN H ET AL. Association of missense and 50-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702–705.
PRIYADARSHI A, KHUDER SA, SCHAUB EA SS. A metaanalysis of Parkinson’s disease and exposure to pesticides. Neurotoxicology. 2000;21:435 - 440.
PRIYADARSHI A, KHUDER SA, SCHAUB EA SS. A metaanalysis of Parkinson’s disease and exposure to pesticides. Neurotoxicology. 2000;21:435 - 440.
SEIDLER A, HELLENBRAND W, ROBRA BP, VIEREGGE P, NISCHAN P, JOERG J ET AL. Possible environmental, occupational, and other etiologic factors for Parkinson’s disease: a case-control study in Germany. Neurology. 1996;46:1275–1284.
WECHSLER LS, CHECKOWAY H, FRANKLIN GM CL. A pilot study of occupational and environmental risk factors for Parkinson’s disease. Neurotoxicology. 1991;12:387–392
ASCHERIO A, CHEN H, WEISSKOPF MG, O’REILLY E, MCCULLOUGH ML, CALLE EE ET AL. Pesticide exposure and risk for Parkinson’s disease. Ann Neurol. 2006;60:197–203.
GOLDMAN SM, TANNER CM, OLANOW CW, WATTS RL, FIELD RD LJ. Occupation and parkinsonism in three movement disorders clinics. Neurology. 2005;65:1430–1435.
TSUI JK, CALNE DB, WANG Y, SCHULZER M MS. Occupational risk factors in Parkinson’s disease. Can J Public Health. 1999;90:334–337.
HF. D. Tobacco consumption and mortality from cancer and other diseases. Public Health Rep. 1959;74:581–593.
HA. K. The Dorn study of smoking and mortality among U.S. veterans: report on eight and one-half years of observation. Natl Cancer Inst Monogr. 1966;19:1–125.
EC. H. Smoking in relation to the death rates of one million men and women. Natl Cancer Inst Monogr. 1966;19:127–204.
DOLL R PR. Mortality in relation to smoking: 20 years’ observations on male British doctors. Br Med J. 1976;2:1525–1536.
HERNAN MA, TAKKOUCHE B, CAAMANO-ISORNA F G-OJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol. 2002;52:276–284.
ALLAM MF, DEL CASTILLO AS NR. Parkinson’s disease, smoking and family history: meta-analysis. Eur J Neurol. 2003;10:59–62.
RITZ B, ASCHERIO A, CHECKOWAY H, MARDER KS, NELSON LM, ROCCA WA ET AL. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol. 2007;64:990–997.
CHEN H, HUANG X, GUO X, MAILMAN RB, PARK Y, KAMEL F ET AL. Smoking duration, intensity, and risk of Parkinson disease. Neurology. 2010;74:878–884.
A. P-H. Risk factors for parkinson’s disease: the leisure world cohort study. Neuroepidemiology. 2001;20:118–124.
WIRDEFELDT K, GATZ M, PAWITAN Y PN. Risk and protective factors for Parkinson’s disease: a study in Swedish twins. Ann Neurol. 2005;57:27–33
HERNAN MA, TAKKOUCHE B, CAAMANO-ISORNA F G-OJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol. 2002;52:276–284.
TAN LC, KOH WP, YUAN JM, WANG R, AU WL, TAN JH ET AL. Differential effects of black versus green tea on risk of Parkinson’s disease in the Singapore Chinese Health Study. Am J Epidemiol. 2008;167:553–560.
DOTY RL, DEEMS DA SS. Olfactory dysfunction in par- kinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology. 1988;38:1237–1244.
HAWKES CH, SHEPHARD BC DS. Olfactory dysfunction in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;62:436–446
GUILLARD A, CHASTANG C FG. Long-term study of 416 cases of Parkinson disease: prognostic factors and therapeutic implications. Rev Neurol (Paris). 1986;142:207–214.
GUILLARD A, CC. Long-term prognostic factors in Parkinson’s disease. Rev Neurol (Paris). 1978;134:341–354.
GOETZ CG, TANNER CM, STEBBINS GT BA. Risk factors for progression in Parkinson’s disease. Neurology. 1988;38:1841–1844.
JANKOVIC J KA. Functional decline in Parkinson disease. Arch Neurol. 2001;58:1611–1615
HOEHN MM YM. Parkinsonism: onset, progres- sion, and mortality. Neurology. 1967;17:427–442.
CONNIE MARRAS, MD; PAULA ROCHON, MD, MPH; ANTHONY E. LANG M. Predicting Motor Decline and disability in Parkinson Disease. A Systematic Review. Arch Neurology. 2002;59:1724–1728.
DIAMOND SG, MARKHAM CH, HOEHN MM, MCDOWELL FH MM. Effect of age at onset on progression and mortality in Parkinson’s disease. Neurology. 1989;39:1187–1190.
HELY MA, MORRIS JG, TRAFICANTE R, REID WG, O’SULLIVAN DJ WP. The Sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry. 1999;67:300–307.
LOUIS ED, TANG MX, COTE L, ALFARO B, MEJIA H MK. Progression of parkinsonian signs in Parkinson disease. Arch Neurol. 1999;56:334–337.
STARKSTEIN SE, MAYBERG HS, LEIGUARDA R, PREZIOSI TJ RR. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1992;55:377–382.
LUCKING CB, DURR A, BONIFATI V ET AL. Association between early-onset Parkinson’s disease and mutations in the parkin gene. N Engl J Med. 2000;342:1560–1567
GOETZ CG, STEBBINS GT BL. Differential progression of motor impairment in levodopa treated Parkinson’s disease. Mov Disord. 2000;15:479–484.
MCDERMOTT MP, JANKOVIC J, CARTER J, ET AL. For TPSG. Factors predictive of the need for levodopa therapy in early, untreated Parkinson’s disease. Arch Neurol. 1995;52:565–570.
POST B, MERKUS MP, DE HAAN RJ, SPEELMAN JD. Prognostic factors for the progression of Parkinson’s disease: a systematic review. Movement disorders: official journal of the Movement Disorder Society. 2007;22(13):1839–1851.
SUCHOWERSKY O, REICH S, PERLMUTTER J, ZESIEWICZ T, GRONSETH G WW. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidencebased review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:968–975.
SCHRAG A, DODEL R, SPOTTKE A, BORNSCHEIN B, SIEBERT U QN. Rate of clinical progression in Parkinson’s disease. A prospective study. Mov Disord. 2007;22:938–945
ALVES G, WENTZEL-LARSEN T, AARSLAND D LJ. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology. 2005;65:1436–1441
POST B, MUSLIMOVIC D, VAN GELOVEN N, SPEELMAN JD, SCHMAND B, DE HAAN RJ. Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society. 2011;26(3):449–456.
VELSEBOER D, BROEDERS M, POST B. Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD. Neurology. 2013;80:627–33.
MARTI P, CUBO ´N-M´* AE. Scales to measure parkinsonism. In: Handbook of Clinical Neurology, Vol. 83 (3rd series) Parkinson’s disease and related disorders, Part I. 2007: 291–327.
Fahn S, Elton RL M of the UDC(1987). Unified Parkinson’s disease rating scale. S Fahn, CD Marsden, DB Calne MG (Eds., editor. Recent Developments in Parkinson’s Disease, Vol. 2, Mac- millan Health Care Information, F. 153–164.
Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008; 23(15):2129–2170.
GOETZ CG, POEWE W, RASCOL O, SAMPAIO C, STEBBINS GT, COUNSELL C, ET AL. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Movement disorders: official journal of the Movement Disorder Society. 2004;19(9):1020–1028
STEBBINS GT, GOETZ CG LA ET AL. Factor analysis of the motor section of the Unified Parkinson’s Disease Rating scale during the off-state. Mov Disord. 1999;14:585–589.
EIDELBERG D, MOELLER JR IT ET AL. Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET. J Nucl Med. 1995;36:378–383
ZHAO YJ, WEE HL, CHAN Y-H, SEAH SH, AU WL, LAU PN, ET AL. Progression of Parkinson’s disease as evaluated by Hoehn and Yahr stage transition times. Mov Disord. 2010:25(6):710–716.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.